Evaluation of a Three Dimensional Functional Metabolic Imaging and Risk Assessment System in Classifying Women for Likelihood of Breast Cancer

Not Applicable

• Conditions: Breast Cancer
• Interventions: Device: MIRA device imaging

• Registration Number: NCT03080155
• Lead Sponsor: Real Imaging Ltd.

Brief Summary

The purpose of the study is to assess the effectiveness of MIRA in classifying women with dense breast tissue for supplemental breast MRI. To assess the effectiveness of MIRA for correctly classifying women with breast cancer and to evaluate the safety of the device.

In women above 30 years old who are undergoing MRI or are scheduled for image-guided needle biopsy due to lesions detected by other imaging modalities.

Detailed Description

Not available

Study Timeline

• Study Start: 2016-09
• Study First Submitted: 2017-03-07
• Study First Submitted QC: 2017-03-09
• Study First Posted: 2017-03-15
• Status Verified: 2018-06
• Last Update Submitted: 2018-06-17
• Last Update Posted: 2018-06-19
• Primary Completion: 2018-09
• Study Completion: 2018-10

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 680

Inclusion Criteria

• Women who are between 30 to 70 years of age and who are asymptomatic and scheduled to undergo routine breast cancer screening (MRI and/or mammography) OR
• Women who are between 30 to 79 years of age and scheduled for image-guided needle biopsy as a result of findings obtained during standard of care imaging modalities (mammography, ultrasound and/or MRI) performed at the clinical site that participates in the study.

Exclusion Criteria

1. Contraindication to bilateral mammography or MRI.
2. Subjects who are unable to read, understand and execute the informed consent procedure.
3. Subjects who have had mammography, ultrasound or MRI examination performed on the day of the study prior to MIRA scan.
4. Subjects who have significant existing breast trauma.
5. Subjects who have undergone lumpectomy/mastectomy.
6. Subjects who have undergone breast reduction or breast augmentation.
7. Subjects who have undergone any other type of breast surgery.
8. Subjects who have large breast scar / Breast deformation.
9. Subjects who have undergone a breast needle biopsy within the 6-month period prior to their intended enrollment into the study.
10. Subjects who have a temperature > 37.8C degrees on the day of the MIRA imaging.
11. Subjects who are pregnant or lactating.
12. Subjects who have had placement of an internal breast marker.
13. Subjects with known Raynaud's Disease.
14. Subjects that are claustrophobic or have physical limitations that do not allow them to sit in the system chair for the required imaging session.
15. Subjects with implanted pacemaker/defibrillator, implanted venous access device (portacath) or other implanted devices.
16. Inmates or mentally disabled individuals.
17. Subjects with a BI-RADS category 6 (e.g. for which mammogram was performed for the purpose of planning cancer therapy).
18. Subjects who participated in the Calibration Phase will not be able to participate in the Testing Phase.
19. Subjects currently participating in another investigational clinical study.
20. Subjects undergoing breast MR for pre-staging.
21. Subjects with known Mastitis

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
MIRA device imaging	MIRA device imaging	MIRA Device imaging for adjunctive detection of breast cancer

Primary Outcome Measures

Name	Time	Method
determining MIRA's PPV (positive predictive value)	24 months	* The positive predictive value (and the amount of false-positive diagnoses) of MIRA will be determined using positive MRI (MRI BI-RADS \>= 3) as a reference test in cohort of women with negative (Mammography BI-RADS 1 or 2).; * The positive predictive value (and the amount of false-positive diagnoses) of MIRA will be determined using the histological diagnosis as the reference test in ALL women participated in the study.

Trial Locations

Locations (1)

BrustZentrum; 🇩🇪 Göttingen, Germany